Research programme: anti-infectives - Echelon Biosciences

Drug Profile

Research programme: anti-infectives - Echelon Biosciences

Alternative Names: Anti-infectives research programme - Echelon Biosciences; Antituberculars research programme - Echelon Biosciences

Latest Information Update: 11 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Echelon Biosciences
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Tuberculosis

Most Recent Events

  • 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris
  • 09 Jul 2003 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 09 Jul 2003 Preclinical trials in Tuberculosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top